1. Market Research
  2. > Pathology
47 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Companion Diagnostics Services Market, 2020-2030

  • $ 4899
  • January 2020
  • 350 pages

Lymphoma by Affiliated Biomarkers Figure ##. ## Clinical Trial Analysis: Distribution of Trials of the Ovarian Cancer by Affiliated Biomarkers Figure ##. ## Clinical Trial Analysis: Distribution of Trials of the Prostate Cancer by Affiliated Biomarkers Figure ##. ## Clinical Trial Analysis: Di

  • Biomarker
  • Clinical Trial
  • Diagnostics
  • Lymphoma
  • World

CAR-T Therapies Market (2nd Edition), 2019-2030

  • $ 3999
  • August 2019
  • 580 pages

Leukemia and Lymphoma ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

Global T-Cell (CAR-T TCR and TIL) Therapy Market (4th Edition) 2019-2030

  • $ 4499
  • July 2019
  • 800 pages

Leukemia and Lymphoma ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030

  • $ 4499
  • April 2019
  • 372 pages

Lymphoma: Number of Trials and Affiliated Biomarkers Please contact our Customer Support Center to get the complete Table of Contents INTRODUCTION Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; t

  • Biomarker
  • Biotechnology
  • Genomics Proteomics And Enabling Technology
  • Lymphoma

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • $ 3499
  • April 2018
  • 850 pages

LEUKEMIA AND LYMPHOMA ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy

CAR-T Therapies Market, 2018-2030

  • $ 3499
  • July 2018
  • 550 pages

Leukemia and Lymphoma ##. ##. ##. ##.

  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • China
  • United States

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

  • $ 3499
  • May 2018
  • 306 pages

IT IS TYPICALLY USED FOR PATIENTS SUFFERING FROM LEUKEMIA, LYMPHOMA AND MULTIPLE MYELOMA.

  • Cancer
  • Lymphoma
  • North America
  • United States
  • World

ADC Contract Manufacturing Market (3rd Edition), 2018-2030

  • $ 3499
  • September 2018
  • 380 pages

LYMPHOMA, POST-TRANSPLANT HODGKIN' S CONSOLIDATION RELAPSED, REFRACTORY ALL HER##-POSITIVE METASTATIC BREAST CANCER (SECOND LINE) TABLE ##. ## ADC THERAPEUTICS: CLINICAL PIPELINE ## Information in this report (and specifically this table/ figure) has been identified from publicly avai

  • Clinical Trial
  • Lymphoma
  • United States
  • Abzena plc
  • Catalent Pharma Solutions, Inc.

Computer-Aided Drug Discovery Services Market, 2018-2030

  • $ 3499
  • June 2018
  • 315 pages

LEUKEMIA AND LYMPHOMA SOCIETY ##.

  • Drug Development
  • Lymphoma
  • Pharmaceutical
  • BioNTech AG.
  • Evotec AG

Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030

  • $ 3499
  • April 2018
  • 449 pages

THIS PROGRAM TARGETS VARIOUS B CELL MALIGNANCIES, SUCH AS CHRONIC LYMPHOCYTIC LEUKEMIA, B-CELL ACUTE LYMPHOCYTIC LEUKEMIA AND DIFFUSE LARGE BCELL LYMPHOMA.

  • DNA
  • Gene Therapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy

Cancer Stem Cell Therapies Market, 2017-2030

  • $ 2499
  • December 2017
  • 270 pages

BMI##, ONE OF THE CORE MEMBERS OF THE PRC## COMPLEX, WAS IDENTIFIED AS AN ONCOGENE THAT COOPERATES WITH C-MYC, A REGULATOR GENE THAT CODES FOR A TRANSCRIPTION FACTOR, IN THE INITIATION OF LYMPHOMA.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • North America
  • United States

Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030

  • $ 2349
  • October 2016
  • 245 pages

AUSTRALASIAN LEUKEMIA AND LYMPHOMA GROUP ##.

  • Lymphoma
  • Therapy
  • United States
  • Almac Discovery Ltd.
  • Celgene Corporation

HDAC Inhibitors Market, 2016 - 2026

  • $ 2349
  • August 2016
  • 233 pages

LEUKEMIA AND LYMPHOMA SOCIETY ##.

  • Clinical Trial
  • Lymphoma
  • Therapy
  • North America
  • United States

Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017 - 2030

  • $ 2499
  • July 2017
  • 450 pages

` Sample Pages Microbiome Therapeutics and Diagnostics Market (##nd Edition), 2017-2030 2017 THIS PAGE IS INTENTIONALLY LEFT BLANK Copyright © 2017 Roots Analysis Private Ltd.

  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • North America
  • United States

Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030

  • $ 2499
  • November 2017
  • 260 pages

IN ADDITION, AT THE TIME OF PUBLICATION OF THIS STUDY, SHIRE HAD PLANS TO COMPLETE THE US FILING FOR SHP## (ACUTE LYMPHOBLASTIC LYMPHOMA (ALL)) AND SHP## (CHRONIC CONSTIPATION) IN FOURTH QUARTER OF 2017.

  • Diagnostics
  • Lymphoma
  • Therapy
  • United States
  • Molecular Partners AG

Cancer Metabolism Based Therapeutics, 2017-2030

  • $ 2499
  • April 2017
  • 263 pages

This leads to the recapitulation of the B cell lymphoma ## (BCL##) family of proteins, which are responsible for cell death.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • North America
  • United States

CD19 Therapeutics Market, 2016 - 2030

  • $ 2199
  • March 2016
  • 302 pages

LYMPHOMA CURRENT TREATMENT LANDSCAPE FOR LEUKEMIA AND LYMPHOMA LEUKEMIA/ LYMPHOMA AUTOIMMUNE DISORDERS: A POTENTIAL AREA FOR ANTI-CD## DRUGS MARKET FORECAST ##. ##.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • North America
  • United States

Cell Line Development Services Market, 2017-2027

  • $ 2499
  • July 2017
  • 278 pages

According to the company, UniAbs were discovered using TeneoBio' s proprietary TeneoSeek discovery engine and the UniRat Human Heavy-Chain Antibody Platform, for the treatment of multiple myeloma, lymphoma and prostate cancer.

  • Biopharmaceutical
  • Cell Therapy
  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical

Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017 - 2030

  • $ 2499
  • May 2017
  • 450 pages

IN MAY 2013, QIAGEN ENTERED INTO AN AGREEMENT WITH THE BC CANCER AGENCY FOR SEVERAL LYMPHOMA RELATED BIOMARKERS, INCLUDING THE EZH## Y## MUTATION BIOMARKER.

  • Diagnostics
  • Genetic Testing
  • Lymphoma
  • North America
  • United States
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on